ENZYME INHIBITORS
Clinical trials for ENZYME INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new ENZYME INHIBITORS trials appear
Sign up with your email to follow new studies for ENZYME INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a targeted drug delay prostate cancer progression?
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…
Matched conditions: ENZYME INHIBITORS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy
Disease control OngoingThis phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to…
Matched conditions: ENZYME INHIBITORS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC